Table 3.
Summary of blood chemistry, electrolytes, biomarkers, thoracic radiography, and echocardiography in study period.
| Parameters | Range | DAY 0 | DAY 7 | DAY 14 | DAY 28 | DAY 56 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| G1 | G2 | G1 | G2 | G1 | G2 | G1 | G2 | G1 | G2 | ||
| BUN (mg/dL) | 16–36 | 38.1 | 32.6 | 43.6 | 33.9 | 38.1 | 40.5 | 38.9 | 33.4 | 39.1 | 34.9 |
| ± | 43.7 | 44.3 | 31.8 | 26.0 | 22.1 | 45.1 | 43.4 | 44.0 | 23.1 | 43.9 | |
| CRE (mg/dL) | 0.8–1.6 | 1.1 | 1.1 | 1.4 | 1.3 | 1.3 | 1.3 | 1.1 | 1.1 | 1.2 | 1.5 |
| ± | 0.6 | 0.5 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.6 | 0.6 | 1.6 | |
| ALP (U/L) | 14–111 | 169.0 | 189.3 | 173.3 | 184.5 | 122.0* | 169.8 | 167.8 | 184.7 | 146.5 | 172.4 |
| ± | 333.8 | 338.7 | 292.8 | 302.7 | 129.2 | 266.4 | 334.1 | 339.8 | 160.2 | 337.4 | |
| ALT (U/L) | 12–130 | 79.4 | 85.9 | 94.1 | 76.5 | 64.8* | 79.3 | 76.4 | 85.5 | 75.6 | 85.3 |
| ± | 86.2 | 90.2 | 108.9 | 57.4 | 37.4 | 48.9 | 86.6 | 90.5 | 60.7 | 90.9 | |
| P (mg/dL) | 3.1–7.5 | 4.5 | 4.3 | 3.9 | 4.4 | 4.0 | 4.4 | 4.3 | 4.3 | 3.9 | 4.3 |
| ± | 1.9 | 1.8 | 0.8 | 2.5 | 0.9 | 2.4 | 2.0 | 1.7 | 1.0 | 1.8 | |
| Na (mEq/L) | 149–157 | 146.6 | 147.1 | 145.2 | 145.8 | 147.8 | 146.8 | 146.8 | 147.6 | 144.8 | 147.5 |
| ± | 6.3 | 4.0 | 6.6 | 4.9 | 6.3 | 5.5 | 6.5 | 5.3 | 6.9 | 12.7 | |
| K (mEq/L) | 3.3–4.5 | 4.2 | 4.1 | 4.3 | 4.2 | 4.2 | 3.9 | 4.2 | 4.0 | 4.3 | 4.1 |
| ± | 0.6 | 0.5 | 0.6 | 0.6 | 0.9 | 0.7 | 0.5 | 0.4 | 0.6 | 0.7 | |
| Cl (mEq/L) | 117–127 | 111.4 | 109.8 | 109.9 | 109.0 | 111.5 | 109.3 | 111.0 | 109.3 | 110.2 | 110.2 |
| ± | 6.3 | 5.7 | 7.8 | 5.0 | 4.9 | 4.2 | 6.0 | 4.7 | 6.6 | 9.8 | |
| cPL (ng/mL) | <50 | 109.7 | 91.6 | 89.7 | 75.4 | 101.5 | 62.9 | 112.7 | 82.2 | 114.5 | 89.3 |
| ± | 168.6 | 108.7 | 102.4 | 83.7 | 123.1 | 31.1 | 168.4 | 74.3 | 239.5 | 83.2 | |
| SDMA (μg/dL) | <17 | 15.5 | 17.3 | 17.6 | 17.1 | 18.0 | 16.8 | 16.1 | 17.4 | 19.6 | 17.3 |
| ± | 9.0 | 11.7 | 11.1 | 10.0 | 11.9 | 11.6 | 8.7 | 10.5 | 17.0 | 10.4 | |
| NT-proBNP (pmol/L) | <900 | 6,783 | 6,916 | 4533*,$ | 5,066$ | 2,783$ | 2,700$ | 2,433$ | 2,616$ | 2150*,$ | 2,683$ |
| ± | 1985 | 1916 | 1,425 | 1,512 | 1,393 | 1,494 | 1,179 | 1,406 | 1,018 | 1,476 | |
| VHS | 8.5–10.5 | 12.3 | 11.4 | 11.8 | 11.1 | 11.5 | 10.9 | 11.7 | 11.0 | 11.2 | 11.2 |
| ± | 1.0 | 1.1 | 1.0 | 0.9 | 0.9 | 0.7 | 0.4 | 0.9 | 0.8 | 1.5 | |
| Lung field | 0 | 0.8 | 0.7 | 0.3*,$ | 0.4 | 0.2*,$ | 0.3$ | 0.2*,$ | 0.3$ | 0.2*,$ | 0.3$ |
| ± | 0.9 | 0.8 | 0.5 | 0.7 | 0.4 | 0.5 | 0.4 | 0.7 | 0.4 | 0.7 | |
| LA/Ao | <1.4 | 2.3 | 2.3 | 2.0 | 2.0 | 2.0$ | 1.9 | 1.9$ | 2.0$ | 1.9$ | 2.1$ |
| ± | 0.3 | 0.3 | 0.4 | 0.4 | 0.5 | 0.4 | 0.3 | 0.4 | 0.4 | 0.5 | |
| LVIDd/Ao | <2.0 | 2.6 | 2.5 | 2.4*,$ | 2.2$ | 2.4$ | 2.2$ | 2.3$ | 2.2$ | 2.3$ | 2.3$ |
| ± | 0.5 | 0.3 | 0.5 | 0.2 | 0.5 | 0.2 | 0.3 | 0.2 | 0.5 | 0.4 | |
| MVE (m/s) | <0.8 | 1.2 | 1.3 | 1.0*,$ | 1.1$ | 0.9*,$ | 1.0$ | 0.9*,$ | 1.0$ | 0.9*,$ | 1.1$ |
| ± | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | |
*p < 0.05 Group 1 vs. Group 2 $p < 0.05 compared to Day 0.